Lucas Gomes Sapienza1, Michael Jenwei Chen2, Maria José Leite Gomes3, David B Mansur4. 1. Instituto COI, MD.X Barra Medical Center, Av. das Américas, 6.205 Loja E - Barra da Tijuca, 22793-080 Rio de Janeiro, Brazil; Antonio Cândido Camargo Cancer Center - ACCCC, R. Professor Antônio Prudente, 211 - Liberdade, São Paulo, SP CEP 01509-010, Brazil. 2. Antonio Cândido Camargo Cancer Center - ACCCC, R. Professor Antônio Prudente, 211 - Liberdade, São Paulo, SP CEP 01509-010, Brazil. 3. Hospital Federal Servidores do Estado do Rio de Janeiro - HFSE, Rua Sacadura Cabral, 178, CEP 20221-903 Rio de Janeiro, RJ, Brazil. 4. U.H. Seidman Cancer Cente, 11100 Euclid Ave., Cleveland, OH 44106, United States.
Abstract
AIM: To evaluate the unintentional coverage of the internal mammary chain (IMC) with tangential fields irradiation to the breast, and its relation with the type of surgery employed. BACKGROUND: The dose distribution in regions adjacent to the treatment targets (mammary gland or chest wall), with incidental irradiation of the IMC, could translate into clinical benefit, due to the proximity of these regions. MATERIALS AND METHODS: One hundred and twelve consecutive conformal radiotherapy plans were correlating the average dose to the IMC with the type of surgery employed, the extent of disease and the irradiation techniques. RESULTS: The mean doses to IMC after modified radical mastectomy (MRM), modified radical mastectomy with immediate reconstruction (MRM + R), and breast conservative surgery (BCS) were 30.34 Gy, 30.26 Gy, and 18.67 Gy, respectively. Significant differences were identified between patients who underwent MRM or MRM + R over BCS (p = 0.01 and 0.003, respectively), but not between MRM and MRM + R (p = 0.88). Mean doses to IMC were greater in patients with T3-T4 tumors when compared with more initial stages (≤T2) (p = 0.0096). The lymph node involvement also correlated with higher average doses to IMC (node positive: 26.1 Gy × node negative: 17.8 Gy, p = 0.0017). CONCLUSIONS: The moderate dose level to the IMC in the unintentional irradiation scenario seems to be insufficient to treat the subclinical disease, although it could have an impact in patients undergoing mastectomy.
AIM: To evaluate the unintentional coverage of the internal mammary chain (IMC) with tangential fields irradiation to the breast, and its relation with the type of surgery employed. BACKGROUND: The dose distribution in regions adjacent to the treatment targets (mammary gland or chest wall), with incidental irradiation of the IMC, could translate into clinical benefit, due to the proximity of these regions. MATERIALS AND METHODS: One hundred and twelve consecutive conformal radiotherapy plans were correlating the average dose to the IMC with the type of surgery employed, the extent of disease and the irradiation techniques. RESULTS: The mean doses to IMC after modified radical mastectomy (MRM), modified radical mastectomy with immediate reconstruction (MRM + R), and breast conservative surgery (BCS) were 30.34 Gy, 30.26 Gy, and 18.67 Gy, respectively. Significant differences were identified between patients who underwent MRM or MRM + R over BCS (p = 0.01 and 0.003, respectively), but not between MRM and MRM + R (p = 0.88). Mean doses to IMC were greater in patients with T3-T4 tumors when compared with more initial stages (≤T2) (p = 0.0096). The lymph node involvement also correlated with higher average doses to IMC (node positive: 26.1 Gy × node negative: 17.8 Gy, p = 0.0017). CONCLUSIONS: The moderate dose level to the IMC in the unintentional irradiation scenario seems to be insufficient to treat the subclinical disease, although it could have an impact in patients undergoing mastectomy.
Entities:
Keywords:
3DCRT; Breast cancer; Internal mammary chain; Radiotherapy; Unintentional irradiation
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: K E Rosenzweig; S E Sim; B Mychalczak; L E Braban; R Schindelheim; S A Leibel Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-01 Impact factor: 7.038
Authors: B Fowble; A Hanlon; G Freedman; N Nicolaou; J Hoffman; E Sigurdson; M Boraas; M Torosian; L Goldstein Journal: Int J Radiat Oncol Biol Phys Date: 2000-07-01 Impact factor: 7.038
Authors: L B Marks; M E Hebert; G Bentel; D P Spencer; G W Sherouse; L R Prosnitz Journal: Int J Radiat Oncol Biol Phys Date: 1994-07-01 Impact factor: 7.038